Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Immatics

Immatics
2000 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Series E LATEST DEAL TYPE
$58M LATEST DEAL AMOUNT
24 INVESTORS
Description

Developer of immunotherapies designed to treat cancer. The company's immunotherapies use natural or engineered T cells to fight cancer as well as the proprietary approaches to producing Adoptive Cell Therapies are directed against targets, which will transform the current landscape of tumor therapy, providing doctors with a way to improve the length and quality of lives of cancer patients.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Paul-Ehrlich-Str. 15
  • 72076 Tübingen
  • Germany

+49 07071 00000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Immatics’s full profile, request a free trial.

Immatics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series E) 04-Oct-2017 $58M 00000 Completed Clinical Trials - General
9. Grant 02-Mar-2015 000.00 00000 Completed Clinical Trials - General
8. Later Stage VC (Series D) 16-Jul-2014 000.00 00000 00000 Completed Clinical Trials - General
7. Later Stage VC (Series C) 21-Sep-2010 000.00 00000 Completed Clinical Trials - General
6. Grant 07-Jul-2008 00.000 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series B) 08-Feb-2007 000.00 000.00 000.00 Completed Clinical Trials - General
4. Grant 06-Sep-2006 00000 000.00 Completed Clinical Trials - General
3. Grant 01-Aug-2005 00000 000.00 Completed Startup
2. Early Stage VC (Series A) 11-Feb-2004 $17.6M $17.6M Completed Startup
1. Grant 24-Jun-2003 $551K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Immatics Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gadeta Venture Capital-Backed Utrecht, Netherlands 00.000 00000000000 00.000
00000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
0000 000000000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 0000 00000000000 0000
To view this company’s complete list of competitors, request access »

Immatics Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Amgen VC-Backed Company Minority 000 0000 000000 0
LSG Holdings Family Office Minority 000 0000 000000 0
NS Investments Venture Capital Minority 000 0000 000000 0
Cancer Prevention and Research Institute of Texas Government 000 0000 000000 0
AT Impf Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 24 investors. Get the full list »

Immatics Executive Team (18)

Name Title Board
Seat
Contact
Info
Harpreet Singh Ph.D Co-Founder, Managing Director & Chief Executive Officer
Thomas Ulmer Managing Director & Chief Financial Officer
Toni Weinschenk Ph.D Co-Founder & Chief Technology Officer
Carsten Reinhardt Ph.D Managing Director & Chief Medical Officer
Rainer Kramer Ph.D Managing Director & Chief Business Officer

6 Former Executives

You’re viewing 5 of 18 executives. Get the full list »

Immatics Board Members (6)

Name Representing Role Since Contact
Info
Christof Hettich Self Board Member 000 0000
Erich Schlick Wellington Partners Board Member 000 0000
Friedrich Von Bohlen Ph.D dievini Board Member 000 0000
Harald Stock Ph.D Self Board Member 000 0000
Matthias Kromayer Ph.D HMW Innovations Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »